- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00528034
Lymphoscintigraphy in Patients With Vaginal Cancer
Lymphoscintigraphy and Selective Lymphatic Mapping in Patients With Invasive Vaginal Cancer
Primary Objectives:
- Determine the feasibility of using pretreatment lymphoscintigraphy to identify the sentinel lymph node(s) in patients with vaginal cancer dispositioned to receive radiation therapy.
- Determine the feasibility of using preoperative lymphoscintigraphy and intraoperative lymphatic mapping to identify the sentinel lymph node(s) in patients with vaginal cancer dispositioned to undergo surgery and bilateral lymph node dissection.
Study Overview
Detailed Description
The treatment of vaginal cancer is usually surgical removal of the vaginal tumor with removal of lymph nodes in the groin and/or pelvis. Patients who are not eligible to receive surgery usually receive radiation therapy.
Lymph nodes are a common site for the spread of vaginal cancer. Lymphatic mapping has been used in patients with other types of cancer to identify the "sentinel" lymph node. The sentinel lymph node is the lymph node believed to be at greatest risk for spread of the cancer. If the sentinel node does not contain cancer cells, then the remaining lymph nodes are almost always cancer free.
This research study will find out if the sentinel node concept can be applied to patients with vaginal cancer. The sentinel lymph node will be identified using a scan called "lymphoscintigraphy". A very small amount (less than one tenth of a teaspoon) of a radioactive material is injected around the edge of the tumor in the vagina, followed immediately by the scan. The scan is done in the Nuclear Medicine Department of M. D. Anderson before the patient has surgery or begins radiation therapy.
The dose of radiation injected into the vagina is much less than the dose received from a chest x-ray and therefore there are no special precautions needed after the injection. If the treatment plan is surgery, a second injection of the radioactive material may be necessary on the day of the operation because the radiation fades quickly. Patients who receive radiation therapy will not need a second injection. The radiation oncologist might use the information collected from the scan to help with treatment planning.
For patients having surgery, a special hand held instrument that measures radioactivity (similar to a Geiger counter) is used to help identify the location of the sentinel lymph node before and after the operation begins. Blue dye is also used to find the sentinel node. This requires the injection of up to a teaspoon of material called Isosulfan Blue around the tumor in the vagina. This is done while the patient is under anesthesia. The surgeon can then identify the sentinel node by its color (blue) and by its level of radioactivity (using the gamma counter).
Patients will be notified of the results of the mapping and lymphoscintigraphy during their hospitalization or their first clinic visit, depending on whether or not they had surgery.
This is an investigational study. Eighteen patients will take part in this study. All will be enrolled at M. D. Anderson.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- U.T.M.D. Anderson Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients must have invasive vaginal cancer, any histology, any stage.
- Patients with prior excision of the primary are eligible.
- Patients with recurrent vaginal cancer who have not had a prior inguinal or groin lymph node dissection.
- Patients undergoing either surgical resection and assessment of inguinal or groin lymph nodes, radiation therapy and/or chemotherapy.
- Patients must sign an IRB approved informed consent.
Exclusion Criteria:
- Known allergy to triphenylmethane compounds.
- Pregnancy.
- Prior radiation therapy to the vagina, vulva, groin or pelvis.
- Prior inguinal, femoral or pelvic lymphadenectomy.
- Patients who are not good surgical candidates.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Lymphoscintigraphy
|
Procedure where a very small amount (less than one tenth of a teaspoon) of a radioactive material is injected around the edge of the tumor in the vagina, followed immediately by the scan.
The scan is done before the patient has surgery or begins radiation therapy.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Identification of sentinel lymph node(s) in patients with vaginal cancer using lymphoscintigraphy and intraoperative lymphatic mapping.
Time Frame: Preoperative and intraoperative, prior to radiation therapy, data collection
|
Preoperative and intraoperative, prior to radiation therapy, data collection
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ID02-239
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Vaginal Cancer
-
National Cancer Institute (NCI)CompletedRecurrent Cervical Cancer | Recurrent Vaginal Cancer | Stage IB Cervical Cancer | Stage II Vaginal Cancer | Stage IIA Cervical Cancer | Stage IIB Cervical Cancer | Stage III Cervical Cancer | Stage III Vaginal Cancer | Stage IVA Cervical Cancer | Stage IVA Vaginal Cancer | Stage IVB Cervical Cancer | Stage IVB... and other conditionsUnited States
-
National Cancer Institute (NCI)NRG OncologyActive, not recruitingCervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Advanced Vaginal Adenocarcinoma | Advanced Vaginal Adenosquamous Carcinoma | Advanced Vaginal Squamous Cell Carcinoma | Cervical Squamous Cell Carcinoma | Stage IB2 Cervical Cancer AJCC v6 and v7 | Stage II Cervical Cancer AJCC v7 | Stage... and other conditionsUnited States, Canada, Puerto Rico
-
Northwestern UniversityNational Cancer Institute (NCI)WithdrawnCervical Intraepithelial Neoplasia Grade 1 | Cervical Intraepithelial Neoplasia Grade 2 | Cervical Intraepithelial Neoplasia Grade 3 | Stage III Vulvar Cancer | Recurrent Cervical Cancer | Recurrent Vaginal Cancer | Recurrent Vulvar Cancer | Stage 0 Cervical Cancer | Stage 0 Vaginal Cancer | Stage 0 Vulvar... and other conditions
-
University of TorontoCanadian Cancer Trials GroupCompletedCervical Cancer | Vulvar Cancer | Vaginal Cancer | Uterine CancerCanada
-
Stanford UniversityNational Cancer Institute (NCI)CompletedCervical Cancer | Endometrial Cancer | Radiation Toxicity | Vaginal CancerUnited States
-
Memorial Sloan Kettering Cancer CenterCompleted
-
Leiden University Medical CenterDutch Cancer SocietyUnknownCervical Cancer | Gynecologic Cancer | Endometrial Cancer | Vaginal CancerNetherlands
-
Dana-Farber Cancer InstituteCompletedCervical Cancer | Vaginal Cancer | Uterine Cancer | Carcinoma of the VulvaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IB2 Cervical Cancer AJCC v8 | Stage II Cervical Cancer AJCC v8 | Stage IIA Cervical Cancer AJCC v8 | Stage IIA1 Cervical Cancer AJCC v8 | Stage IIA2 Cervical Cancer AJCC v8 | Stage IIB Cervical Cancer AJCC v8 | Stage III Cervical Cancer AJCC v8 | Stage IIIA Cervical Cancer AJCC v8 | Stage IIIB... and other conditionsUnited States
-
Memorial Sloan Kettering Cancer CenterCompletedCervical Cancer | Breast Cancer | Ovarian Cancer | Lung Cancer | Prostate Cancer | Bladder Cancer | Vaginal CancerUnited States
Clinical Trials on Lymphoscintigraphy
-
University of Wisconsin, MadisonCompletedCervical CancerUnited States
-
Hospital Angeles del PedregalCompletedLymphedema, Secondary | Lymphedema of Leg | Granuloma, Foreign-BodyMexico
-
Dana-Farber Cancer InstituteRecruitingBreast Cancer | Sentinel Lymph Node | Inflammatory Breast CancerUnited States
-
Catharina Ziekenhuis EindhovenCompleted
-
Assiut UniversityUnknownEarly-stage Breast Cancer
-
Kliniken Essen-MitteGerman Breast GroupCompletedEarly-Stage Breast CarcinomaGermany, Switzerland
-
Kaohsiung Veterans General Hospital.Recruiting
-
European Organisation for Research and Treatment...ALMANAC Trialists Group; Borstkanker Onderzoeksgroup NederlandCompletedBreast CancerNetherlands, United Kingdom, France, Switzerland, Italy, Slovenia, Poland, Turkey
-
Loma Linda UniversityWithdrawn
-
Stanford UniversityWhitaker FoundationCompletedBreast Cancer | Multiple MyelomaUnited States